. 2021 May 20;8(6):1343–1352. doi: 10.1002/acn3.51373
© 2021 Takeda Pharmaceutical. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
Figure 1.
Study design. BID, twice daily; FRDA, Friedreich ataxia.